Related Experiment Videos
Photoradiation therapy of bladder tumours
Progress in Clinical and Biological Research
|January 1, 1984
Summary
Photoradiation therapy (PRT) using hematoporphyrin derivative (HpD) shows promise for superficial bladder tumors. Optimal light intensity and total dose are crucial for effective treatment, with larger tumors being less responsive.
Area of Science:
- Oncology
- Photodynamic Therapy
Background:
- Superficial bladder tumors present a treatment challenge.
- Hematoporphyrin derivative (HpD) is a photosensitizing agent used in photoradiation therapy (PRT).
Purpose of the Study:
- To evaluate the efficacy of photoradiation therapy (PRT) with hematoporphyrin derivative (HpD) for superficial bladder tumors.
- To determine optimal light parameters for PRT in bladder cancer treatment.
Main Methods:
- PRT was administered to 46 superficial bladder tumors in 9 patients using HpD and an argon-dye laser.
- Tumor biopsies were analyzed for HpD localization using fluorospectrophotometry.
- Tumor response was assessed based on varying light intensities and total energy doses.
Main Results:
- Preferential HpD localization was observed in malignant bladder tissues.
- Tumors <1 cm diameter showed higher complete response (CR) rates with light intensity ≥200 mwatts/cm² (15 CR, 5 PR) compared to 150 mwatts/cm² (2 CR, 5 NC).
- Tumors ≤1 cm treated with 100-250 joules/cm² achieved CR in 5 out of 6 cases. Tumors >2 cm showed no CR.
Conclusions:
- PRT with HpD is effective for superficial bladder tumors, particularly those ≤2 cm in size.
- Recommended treatment parameters include light intensity of ≥300 mwatts/cm² for 5-10 minutes and a total light dose of ≥100 joules/cm².
- No early adverse effects were noted, though 4 patients experienced photosensitivity.